Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 2
2007 5
2009 3
2010 6
2011 12
2012 8
2013 17
2014 26
2015 39
2016 45
2017 47
2018 49
2019 35
2020 45
2021 35
2022 40
2023 34
2024 35
2025 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

441 results

Results by year

Filters applied: . Clear all
Page 1
Engaging stemness improves cancer immunotherapy.
Dianat-Moghadam H, Sharifi M, Salehi R, Keshavarz M, Shahgolzari M, Amoozgar Z. Dianat-Moghadam H, et al. Among authors: salehi r. Cancer Lett. 2023 Feb 1;554:216007. doi: 10.1016/j.canlet.2022.216007. Epub 2022 Nov 14. Cancer Lett. 2023. PMID: 36396102 Review.
Immunotherapies targeting tumor vasculature: challenges and opportunities.
Dianat-Moghadam H, Nedaeinia R, Keshavarz M, Azizi M, Kazemi M, Salehi R. Dianat-Moghadam H, et al. Among authors: salehi r. Front Immunol. 2023 Sep 1;14:1226360. doi: 10.3389/fimmu.2023.1226360. eCollection 2023. Front Immunol. 2023. PMID: 37727791 Free PMC article. Review.
CD25 gene polymorphism and multiple sclerosis.
Alsahebfosoul F, Salehi R, Ghaffari S, Jahanbani-Ardakani H, Etemadifar M, Kazemi M, Abtahi SH. Alsahebfosoul F, et al. Among authors: salehi r. Mult Scler Relat Disord. 2017 Nov;18:117-118. doi: 10.1016/j.msard.2017.09.005. Epub 2017 Sep 20. Mult Scler Relat Disord. 2017. PMID: 29141792 No abstract available.
Chitosan-based nanotherapeutics for ovarian cancer treatment.
Alizadeh L, Zarebkohan A, Salehi R, Ajjoolabady A, Rahmati-Yamchi M. Alizadeh L, et al. Among authors: salehi r. J Drug Target. 2019 Sep;27(8):839-852. doi: 10.1080/1061186X.2018.1564923. Epub 2019 Feb 11. J Drug Target. 2019. PMID: 30596291 Review.
Liposome-based drug co-delivery systems in cancer cells.
Zununi Vahed S, Salehi R, Davaran S, Sharifi S. Zununi Vahed S, et al. Among authors: salehi r. Mater Sci Eng C Mater Biol Appl. 2017 Feb 1;71:1327-1341. doi: 10.1016/j.msec.2016.11.073. Epub 2016 Nov 23. Mater Sci Eng C Mater Biol Appl. 2017. PMID: 27987688 Review.
An update on dual targeting strategy for cancer treatment.
Taghipour YD, Zarebkohan A, Salehi R, Rahimi F, Torchilin VP, Hamblin MR, Seifalian A. Taghipour YD, et al. Among authors: salehi r. J Control Release. 2022 Sep;349:67-96. doi: 10.1016/j.jconrel.2022.06.044. Epub 2022 Jul 6. J Control Release. 2022. PMID: 35779656 Review.
Molecular mechanisms of drug resistance in ovarian cancer.
Norouzi-Barough L, Sarookhani MR, Sharifi M, Moghbelinejad S, Jangjoo S, Salehi R. Norouzi-Barough L, et al. Among authors: salehi r. J Cell Physiol. 2018 Jun;233(6):4546-4562. doi: 10.1002/jcp.26289. Epub 2018 Jan 4. J Cell Physiol. 2018. PMID: 29152737 Review.
441 results